7377-48-2

Basic information

• Product Name: 2-amino-6-(biphenyl-4-yl)pyrimidin-4(1H)-one
• CAS NO: 7377-48-2
• Molecular Formula: C₁₆H₁₃N₃O
• Molecular Weight: 263.2939
• Mol File: 7377-48-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 475.3°C at 760 mmHg
• Flash Point: 241.3°C
• Density: 1.26g/cm³
• Vapor Pressure: 3.35E-09mmHg at 25°C
• Refractive Index: 1.667
• CAS DataBase Reference: 2-amino-6-(biphenyl-4-yl)pyrimidin-4(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-6-(biphenyl-4-yl)pyrimidin-4(1H)-one(7377-48-2)
• EPA Substance Registry System: 2-amino-6-(biphenyl-4-yl)pyrimidin-4(1H)-one(7377-48-2)

Safety Data

• Hazardous Substances Data: 7377-48-2(Hazardous Substances Data)

Usage

Chemical Class

Pyrimidine derivatives

Functional Groups

Amino group at the 2-position
Biphenyl group at the 6-position

Applications

Medicinal chemistry
Drug development

Biological Targets

Proteins
Enzymes

Activity Modulation

Interaction with biological targets to modulate their activity

Potential Therapeutic Benefits

Design and synthesis of novel pharmaceutical compounds

Value as a Scaffold

Useful for designing drugs with therapeutic potential

Research Implications

Exploration of its potential as a drug candidate for various diseases and conditions

Upstream product

• 113-00-8 guanidine nitrate 
• 57477-98-2 3-biphenyl-4-yl-3-oxopropionic acid ethyl ester 
• 1194-21-4 2-amino-6-chloro-4-pyrimidinol 
• 144432-80-4 2-(biphenyl-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Downstream Products

• 98305-21-6 2-Amino-6-biphenyl-4-yl-5-iodo-3H-pyrimidin-4-one 
• 98305-20-5 2-Amino-6-biphenyl-4-yl-5-bromo-3H-pyrimidin-4-one 

Relevant articles and documents

Isocytosine-based inhibitors of xanthine oxidase: Design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia

Structure-activity relationship studies were carried out for lead generation following structure-guided design approach from an isocytosine scaffold identified earlier for xanthine oxidase inhibition. A 470-fold improvement in in vitro IC50 was obtained in the process. Five most potent compounds with nanomolar IC50 values were selected for pharmacokinetics and in vivo experiments. The best compound showed good in vivo activity when administered intraperitoneally but was not active by oral route. The results suggest that improvement in oral exposure could improve the in vivo efficacy of this series.